ReviewEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2014
Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review.
Review in European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03363516 (Early Prediction of Mild Cognitive Impairment in Glucose Normotolerant Subjects With 1-hour Post-load Plasma Glucose >155 mg/dL), which is not on this map. Cited by 155 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Prediction of Mild Cognitive Impairment in Glucose Normotolerant Subjects With 1-hour Post-load Plasma Glucose >155 mg/dL
Who cites it
155 citing papers in PubMed, 5 syntheses or guidelines pooled it, 305 citations in OpenAlex.
- Diabetic retinopathy and the risk of all-cause dementia, Alzheimer's disease, and vascular dementia: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Brain-derived neurotrophic factor in diabetes mellitus: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Efficacy of Glucose Metabolism-Related Indexes on the Risk and Severity of Alzheimer's Disease: A Meta-Analysis.Journal of Alzheimer's disease : JAD · 2023Pooled it
- Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer's disease by meta-analysis and adaptive boosting ensemble learning.Alzheimer's research & therapy · 2021Pooled it
- A Systematic Review of MicroRNA Expression as Biomarker of Late-Onset Alzheimer's Disease.Molecular neurobiology · 2019Pooled it
- Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial.Journal of endocrinological investigation · 2024Trial
- Brain-derived neurotrophic factor in diabetes: A promising target for cognitive restoration.iScience · 2026Review
- Metabolite profiling, enzyme inhibition, and in silico analysis of Commiphora gileadensis oleo-gum resin.Die Naturwissenschaften · 2026Article
- The Neuroprotective Role of Exercise in Alzheimer's Disease: An Integrative Review of Animal and Human Studies.Neurology international · 2026Review
- Regorafenib modulates glucose metabolism, insulin/GLP-1 signaling, and tau pathology in an STZ-induced model of Alzheimer's disease.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Intrinsic mechanical vibrations as a missing dimension in amyloid-Frontiers in aging neuroscience · 2026Article
- Can Beetroot (Nutrients · 2025Review
- Article
- Neuroinflammation Based Neurodegenerative In Vitro Model of SH-SY5Y Cells-Differential Effects on Oxidative Stress and Insulin Resistance Relevant to Alzheimer's Pathology.International journal of molecular sciences · 2025Article
- Metabolic Status Modulates Global and Local Brain Age Estimates in Overweight and Obese Adults.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2025Article
- Metabolic Regulation as a Potential Therapeutic Approach for Alzheimer's Disease.Current Alzheimer research · 2025Review
- Relationship between Alzheimer's Disease and Type 2 Diabetes: Critical Review On Cellular and Molecular Common Pathogenic Mechanisms.Current Alzheimer research · 2025Review
- Association between plant-based dietary patterns and dementia among Chinese older adults.Frontiers in nutrition · 2025Article
- GLP-1R as a potential link between diabetes and Alzheimer's disease.Frontiers in aging neuroscience · 2025Review
- Optimization of Glyburide-loaded NanosuspensionsCurrent pharmaceutical design · 2025Article
95 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Alzheimer׳s disease (AD) is the most common cause of dementia in North America. Growing evidence supports the concept that AD is a metabolic disease mediated by impairments in brain insulin responsiveness, glucose utilization, and energy metabolism, which lead to increased oxidative stress, inflammation, and worsening of insulin resistance. In addition, metabolic derangements directly contribute to the structural, functional, molecular, and biochemical abnormalities that characterize AD, including neuronal loss, synaptic disconnection, tau hyperphosphorylation, and amyloid-beta accumulation. Because the fundamental abnormalities in AD represent effects of brain insulin resistance and deficiency, and the molecular and biochemical consequences overlap with Type 1 and Type 2 diabetes, we suggest the term "Type 3 diabetes" to account for the underlying abnormalities associated with AD-type neurodegeneration. In light of the rapid increases in sporadic AD prevalence rates and vastly expanded use of nitrites and nitrates in foods and agricultural products over the past 30-40 years, the potential role of nitrosamine exposures as mediators of Type 3 diabetes is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.